Gammaked (Immune Globul G/Gly/IgA Avg 46) Patent Expiration, LOE Window & CMS Spending

Gammaked (Immune Globul G/Gly/IgA Avg 46) by Kedrion Biophar: Off-Patent Genericized (AB Competition), 0 AB generics, $306.0M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKedrion Biophar
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$306.0M
2024 Medicare Part D Spend$270.0M
2024 Medicaid Spend$36.0M
Reported Wholesale Price Change (CA SB 17)18 WAC filings (max 371.1% 2-yr change)